Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced its plans to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $10 billion. The deal, which has already been approved by the board of directors of both companies, is expected to close in the third quarter of 2026.
Vertex will pay $85 per share in cash for a total equity value of approximately $10 billion, or approximately $8.8 billion net of estimated cash acquired. Vertex expects to finance the acquisition using a combination of cash on hand and debt.